RenovoRx Inc
RNXT
Company Profile
Business description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
Contact
4546 El Camino Real
Suite B1
Los AltosCA94022
USAT: +1 650 284-4433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
Vote in favour of merger for undervalued ASX share
We recommend shareholders vote in favor of its proposed merger.
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,569.10 | 112.30 | 1.33% |
| CAC 40 | 7,623.38 | 148.79 | 1.99% |
| DAX 40 | 20,611.41 | 36.73 | 0.18% |
| Dow JONES (US) | 43,221.55 | 703.27 | 1.65% |
| FTSE 100 | 8,359.19 | 58.06 | 0.70% |
| HKSE | 19,522.89 | 236.82 | 1.23% |
| NASDAQ | 19,511.23 | 466.84 | 2.45% |
| Nikkei 225 | 38,572.60 | 128.02 | 0.33% |
| NZX 50 Index | 13,000.67 | 57.10 | 0.44% |
| S&P 500 | 5,949.91 | 107.00 | 1.83% |
| S&P/ASX 200 | 8,327.00 | 113.70 | 1.38% |
| SSE Composite Index | 3,236.03 | 8.92 | 0.28% |